Similar articles

• Guidelines for treatment with infliximab for Crohn's disease.

  Hommes DW, Oldenburg B, van Bodegraven AA, van Hogezand RA, de Jong DJ, Romberg-Camps MJ, van der Woude J, Dijkstra G; Dutch Initiative on Crohn and Colitis (ICC). Hommes DW, et al. Neth J Med. 2006 Jul-Aug;64(7):219-29. Neth J Med. 2006. PMID: 16929083 Review.
• Infliximab in fistulizing Crohn's disease.

  Osterman MT, Lichtenstein GR. Osterman MT, et al. Gastroenterol Clin North Am. 2006 Dec;35(4):795-820. doi: 10.1016/j.gtc.2006.09.007. Gastroenterol Clin North Am. 2006. PMID: 17129814 Review.
• Maintenance infliximab does not result in increased abscess development in fistulizing Crohn's disease: results from the ACCENT II study.

  Sands BE, Blank MA, Diamond RH, Barrett JP, Van Deventer SJ. Sands BE, et al. Aliment Pharmacol Ther. 2006 Apr 15;23(8):1127-36. doi: 10.1111/j.1365-2036.2006.02878.x. Aliment Pharmacol Ther. 2006. PMID: 16611273 Clinical Trial.
• Combining infliximab with 6-mercaptopurine/azathioprine for fistula therapy in Crohn's disease.

  Ochsenkühn T, Göke B, Sackmann M. Ochsenkühn T, et al. Am J Gastroenterol. 2002 Aug;97(8):2022-5. doi: 10.1111/j.1572-0241.2002.05918.x. Am J Gastroenterol. 2002. PMID: 12190171
• Infliximab maintenance therapy for fistulizing Crohn's disease.

  Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Kamm MA, Korzenik JR, Lashner BA, Onken JE, Rachmilewitz D, Rutgeerts P, Wild G, Wolf DC, Marsters PA, Travers SB, Blank MA, van Deventer SJ. Sands BE, et al. N Engl J Med. 2004 Feb 26;350(9):876-85. doi: 10.1056/NEJMoa030815. N Engl J Med. 2004. PMID: 14985485 Clinical Trial.